Trial · NCT07216794
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in intact HIV-1 deoxyribonucleic acid (DNA) copies by the Intact Proviral DNA Assay (IPDA) in peripheral blood | Baseline to week 24 | |
| Secondary | Amount of ALN excreted after initial dose of ALN | Over 24 hours | |
| Secondary | Peripheral blood CD4+ cell-associated (CA) HIV-1 RNA levels (unspliced and multiply spliced species by quantitative polymerase chain reaction [qPCR]) | At Baseline and Weeks 12, 24 and 32 | |
| Secondary | Number of plasma HIV-1 RNA copies [by single copy assay (SCA)] | At Baseline and Weeks 12, 24 and 32 | |
| Secondary | HIV RNA in the GI tract (RNA scope and spatial immunophenotyping in sigmoidoscopy samples) | Pre-intervention and Weeks 22-24 | |
| Secondary | Number of intact HIV-1 DNA copies by the IPDA in peripheral blood | Weeks 2, 12, and 32 | |
| Secondary | HIV DNA in the GI CD4+ and Vdelta1 (Vd1) T cells (DNA scope in sigmoidoscopy samples) | Pre-intervention and Weeks 22-24 | |
| Secondary | Peripheral blood CD4+ cell-associated (CA) HIV-1 RNA levels (unspliced and multiply spliced species by qPCR) | At Baseline and Weeks 1 and 2 | |
| Secondary | Number of plasma HIV-1 RNA copies (by SCA) | At Baseline and Weeks 1 and 2 | |
| Secondary | Frequency of αβ CD8+ cells by flow cytometry | Pre-intervention and Weeks 1, 12, 24, and 32 | |
| Secondary | Phenotype of αβ CD8+ cells by flow cytometry | Pre-intervention and Weeks 1, 12, 24, and 32 | |
| Secondary | Frequency of γδ cells by flow cytometry | Pre-intervention and Weeks 1, 12, 24, and 32 | |
| Secondary | Phenotype of γδ cells by flow cytometry | Pre-intervention and Weeks 1, 12, 24, and 32 | |
| Secondary | Frequency of NK cells by flow cytometry | Pre-intervention and Weeks 1, 12, 24, and 32 | |
| Secondary | Phenotype of NK cells by flow cytometry | Pre-intervention and Weeks 1, 12, 24, and 32 | |
| Secondary | HIV-specific responses (IFN- γ and GzmB) by Fluorospot | Pre-intervention and Weeks 1, 12, 24, and 32 | |
| Secondary | Presence of plasma markers of inflammation/activation | Pre-intervention and Weeks 1, 12, 24, and 32 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07216794/registered